Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-[4-(Aminosulfonyl)phenyl]propanoic acid is a small molecule compound belonging to the class of phenylpropanoic acids and benzenesulfonamides[1][2][4]. It acts as an experimental inhibitor of carbonic anhydrase isoforms, specifically carbonic anhydrase 1 and carbonic anhydrase 2[1]. These enzymes are involved in the reversible hydration of carbon dioxide and play roles in various physiological processes including pH regulation. The compound has not been approved for clinical use or marketed for any indication, and there are no reported clinical trials beyond preclinical/experimental stages[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[4-(aminosulfonyl)phenyl]propanoic acid.